Clinical Trials COVID-19 Research at Saint John’s Health Center and Saint John’s Cancer Institute Plasma Donations from Recovered COVID-19 Patients

Consider Plasma Donation

As the nation confronts the unprecedented coronavirus pandemic, the Food and Drug Administration (FDA) took an aggressive step forward in the fight against COVID-19.

Red Cross has been asked by the FDA to help identify potential donors in order to urgently increase options for physicians caring for COVID-19 patients.

Providence St. Joseph Health was one of the first organizations in the U.S. to utilize convalescent plasma. Patients who have fully recovered from COVID-19 infection have antibodies in their plasma that can attack the virus and protect them from becoming infected again with coronavirus. Their plasma may be rich with these antibodies that might be helpful in the treatment of COVID-19 infection in others.

Download Flyer

Convalescent Plasma - Treatment of Patients with COVID-19
Convalescent Plasma

Convalescent Plasma

Expanded Access to Convalescent Plasma for Treatment of Patients with COVID-19

Saint John’s Health Center is one Providence St. Joseph Health site collaborating with Mayo Clinic for the FDA approved COVID-19 convalescent plasma patient access program.

This expanded access treatment protocol will provide convalescent plasma to patients in need. Historically, convalescent plasma has been used as a potentially lifesaving treatment when new diseases or infections develop quickly, and no treatments or vaccines were available yet.

For Potential Donors

For Potential Donors

If you have been sick with COVID-19 (shown by a positive test result) AND have one of the following:

a. Complete resolution of symptoms at 28 days prior to donation.

b. Complete resolution of symptoms at least 14 days prior to donation AND negative results for COVID-19.

For Physicians

For Physicians

Interested physicians should contact Santosh Kesari, MD, PhD (Santosh.Kesari@providence.org) or Trevan Fischer, MD (Trevan.Fischer@providence.org) for how to participate in the expanded access program.

For more information, please contact:

Email: COVID19Trials@jwci.org | Phone: 310-582-7437